Employees: 108
Size Sanara MedTech (SMTI) is a United States Health Care company (Medical Specialties) with a market value of $301M, the 3082nd largest of 3,085 United States companies the cockpit tracks. Shares closed at $32.73 on 18 Nov 2026.
Performance Over six months the shares gained 42.3%, against -20.4% for the median peer and -2.2% for the United States market (cap-weighted) — 3rd highest of 21 in its peer set.
Growth Revenue grew 9.8% over the last twelve months (peer median +2.2%); the operating margin is 10.9% (peer median 7.9%).
Valuation It trades at 59.0× forward earnings against a peer median of 17.1× (3rd most expensive of 13).
Price implies For today's price to make sense, revenue must grow about 20% a year for seven years (Req g). Recent delivered growth is +46%, so the hurdle is -26 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 13.9 points above its cost of capital (10.4% WACC).
Next results Next results expected around 31 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $112M | $103M | $86.7M | $65.0M | $45.8M |
| Revenue growth | — | +19% | +33% | +42% | — |
| Gross profit | $102M | $92.9M | $75.7M | $53.5M | $37.1M |
| EBITDA | $14.7M | $11.8M | $4.22M | -$3.99M | -$9.60M |
| Net income | -$3.02M | -$37.6M | -$9.66M | -$4.30M | -$7.94M |
| Free cash flow | $7.29M | $2.16M | -$229,630 | -$3.51M | -$5.70M |
| Capital expenditure | $131,211 | $4.65M | $229,300 | $265,246 | $747,015 |
| Total debt | $48.7M | $48.2M | $32.3M | $11.8M | $819,224 |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | SMTI | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -1.2% | -10.9% | 5th highest of 21 |
| 6-month return | +42.3% | -20.4% | 3rd highest of 21 |
| Distance from 52-week high | -7.8% | -48.0% | 2nd highest of 21 |
| Revenue growth (TTM) | +9.8% | +2.2% | 8th highest of 21 |
| Operating margin | 10.9% | 7.9% | 10th highest of 21 |
| Forward P/E | 59.0× | 17.1× | 3rd most expensive of 13 |
| Growth the price implies (Req g, 7 yrs) | 19.5% | 4.4% | 4th most demanding of 15 |
| Growth delivered (Del g) | +45.9% | +0.2% | highest of 15 |
| Hurdle (Req g minus delivered) | -26.4 pp | +7.9 pp | 3rd least demanding of 15 |
| ROIC minus cost of capital | +13.9 pp | +0.6 pp | 4th highest of 19 |
| EV / EBITDA | 22.7× | 7.8× | 2nd most expensive of 10 |
| Net debt / EBITDA | 2.2× | 1.3× | 3rd most indebted of 10 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Sanara MedTech SMTI | United States | $301M | +42% | +10% | 11% | 59.0× | 19.5% | +45.9% |
| Chongqing Xishan Science and Technology 688576.SS | China | $301M | -40% | -23% | -29% | 12.8× | n/a | n/a |
| Peijia Medical 9996.HK | Hong Kong | $296M | -34% | +21% | -13% | 292.4× | n/a | n/a |
| Kontour (Xi'an) Medical Technology 688314.SS | China | $291M | -46% | +8% | 24% | n/a | 3.1% | +16.4% |
| Japan Eyewear 5889.T | Japan | $318M | -5% | +15% | 32% | 10.7× | -9.4% | +20.2% |
| Shenzhen Bioeasy Biotechnology 300942.SZ | China | $326M | -27% | +12% | -2% | n/a | n/a | n/a |
| Jiangsu Apon Medical Technology 300753.SZ | China | $326M | -34% | -15% | -10% | 862.0× | 20.0% | -5.1% |
| Chemclin Diagnostics 688468.SS | China | $327M | -24% | -10% | 4% | n/a | 15.8% | -4.5% |
| Tauns Laboratories 197A.T | Japan | $327M | -3% | +7% | 29% | 16.7× | n/a | n/a |
| Jiangsu Huayang Intelligent Equipment 301502.SZ | China | $336M | -36% | -5% | 2% | n/a | 34.3% | +0.4% |
| BioNote 377740.KS | South Korea | $337M | -14% | +12% | 18% | 14.4× | -15.0% | -28.5% |
| Nanjing Medlander Medical Technology 688273.SS | China | $337M | -47% | -12% | 8% | 17.5× | 35.3% | +5.2% |
| COLTENE CLTN.SW | Switzerland | $339M | -7% | -2% | 8% | 25.2× | -0.3% | -0.7% |
| YD Bio YDES | United States | $344M | +7% | +17% | -883% | n/a | n/a | n/a |
| Embecta EMBC | United States | $345M | +99% | -8% | 26% | 3.8× | -19.9% | -0.1% |
| IVF HARTMANN VBSN.SW | Switzerland | $352M | -2% | +7% | 14% | n/a | -12.7% | -1.3% |
| Yantai Zhenghai Bio-Tech 300653.SZ | China | $354M | -23% | -8% | 17% | 36.0× | 18.4% | +4.4% |
| Beijing Succeeder Technology 688338.SS | China | $362M | -18% | -4% | 31% | 16.4× | 5.7% | +3.4% |
| Star Sports Medicine 1609.HK | Hong Kong | $364M | -73% | +23% | 37% | n/a | -13.1% | +36.8% |
| Stratec SBS.DE | Germany | $365M | +63% | -6% | 4% | 18.2× | 19.1% | +0.1% |
| CapsoVision CV | United States | $366M | +5% | +15% | -213% | n/a | n/a | n/a |